Over 50 years ago New York Eye and Ear Infirmary of Mount Sinai (NYEE) opened the first retina service in New York City. The service's pioneering ways continue today with advanced surgical and medical treatments for retinal detachments, retinal tears, macular holes, epiretinal membranes, diabetic retinopathy, vein occlusions, wet and dry age-related macular degeneration, inherited retinal dystrophies, and more.
Retinal research, an important aspect of the retina service, keeps New York Eye and Ear Infirmary at the forefront in testing of new therapies including anti-VEGF therapy for the treatment of wet age-related macular degeneration (AMD) and other retinal blood vessel disorders. Ant-VEGF halts the growth of abnormal blood vessel beneath the macula and significantly improves eyesight. NYEE is refining and offering a number of cutting-edge combination therapies for preventing vision loss from AMD and is carrying out research where therapeutic compounds are administered through a delivery system placed in the vitreous, the inner fluid, of the eye.
Difficult retinal detachments and macular disorders are routinely treated at NYEE using standard vitrectomy procedures and state-of-the-art techniques. Over the years, the scope of the Retina Service has expanded from treating primarily retinal detachment and retinal tears to encompassing technologies including angiography, optical coherence tomography, scanning laser polarimetry, and laser treatments. The Retina Center manages more than 40,000 patient visits per year and is involved in research on diabetic retinopathy, genetic causes of macular degeneration and treatments for wet and dry AMD.
- retinal detachments
- retinal tears
- macular holes
- epiretinal membranes
- diabetic retinopathy
- vein occlusions
- wet and dry age-related macular degeneration
- inherited retinal dystrophies